Evaluation of the factors contributing to long-term survival in canine tonsillar squamous cell carcinoma
Evaluation of the factors contributing to long-term survival in canine tonsillar squamous cell carcinoma
复制标题
DOI：
10.1111/avj.12444
复制
发表时间：
2016-06-01
影响因子：
1.1
通讯作者：
North, S.
中科院分区：
文献类型：
--
作者：
Grant, J.;North, S.
ObjectivesTo确定任何预后因素，可能与长期生存的诊断与扁桃体鳞状细胞癌（TSCC）的狗。MethodsThe病历的15只狗治疗TSCC进行了回顾性分析。记录了所有病例的临床表现、临床分期、治疗方法和预后。结果本组犬的中位生存期为243天。1年和2年生存率分别为40%和20%。初始分期的结果对生存率有显著影响，因为仅一侧扁桃体受累且无转移性疾病证据的犬的MST（637.5天）长于初始表现时局部（MST：134天）或远处（MST：75天）转移性疾病或双侧扁桃体受累的犬。延长生存时间的狗接受手术和连续化疗（MST：464.5天）治疗TSCC.Clinical significance这是第一个兽医研究表明TSCC患者的预后和阶段之间的关联在介绍的时候，与长期的生存时间证明了狗与早期疾病的初步治疗方案，其中包括手术和化疗。长期生存与疾病进展的额外手术之间没有明确的联系;然而，需要进一步研究。
ObjectivesTo identify any prognostic factors that may be associated with the long-term survival of dogs diagnosed with tonsillar squamous cell carcinoma (TSCC).MethodsThe medical records of 15 dogs treated for TSCC were reviewed retrospectively. The signalment, presenting signs, clinical stage, treatments and outcome were documented.ResultsThe overall median survival time (MST) of the dogs in the study was 243 days. There was a 1-and 2-year survival of 40% and 20%, respectively. The results of initial staging had a significant effect on survival, as dogs with only one tonsil affected and no evidence of metastatic disease had a longer MST (637.5days) than the dogs with local (MST: 134 days) or distant (MST: 75 days) metastatic disease or bilateral tonsillar involvement at the time of initial presentation. Prolonged survival times were reported for dogs undergoing surgery and adjunctive chemotherapy (MST: 464.5days) for treatment of their TSCC.Clinical significanceThis is the first veterinary study demonstrating an association between prognosis of patients with TSCC and stage at the time of presentation, with long survival times demonstrated for dogs with early-stage disease following an initial treatment protocol that included surgery and chemotherapy. There was no clear association between long survival and additional surgeries for progressive disease; however; further investigation is warranted.